Key Takeaways
- Strong volume-led growth, margin squeeze: Revenue grew double digits across all regions on volume and market share gains, but gross margin fell 80 bps YoY to 50.7% on pricing pressure, while EBITDA margin improved 110 bps YoY to 17.7% on operating leverage.
- Teva facility is the big bet: The acquired Goa plant doubles capacity potential to 800 crore units, requires ₹200 crores total spend, and is expected to close by April 2023, with some revenue generation in the first year itself.
- Backward integration promises 500 bps margin lift: Moving into API manufacturing for captive consumption, with first DMF filing targeted for mid-2023 and profitability upside expected by end of FY24.
- US remains underpenetrated, pipeline building: Management sees current US presence as "just at the tip of the iceberg," expects ~5 ANDA approvals in 2023, and has a healthier roadmap for the next financial year.
- What to watch next quarter: Closure of the Teva acquisition, progress on API DMF filings, trajectory of freight and input cost easing, and any concrete M&A developments in Europe.
Teva Facility Acquisition & Capacity Expansion
- Asset profile: Acquired from Teva India in October 2022, the facility spans 47,597 sq. meters with approvals from EU, Health Canada, and Japanese health authorities, capable of producing tablets, hard capsules, soft gelatin, ointments, creams, and liquids.
- Transaction timeline: Expected to close by April 1, 2023, subject to usual closing conditions, with a 12-month supply arrangement with Teva post-closing.
- Total investment: ₹200 crores including acquisition cost and Capex, spread over the next two years and funded entirely through internal accruals.
- Capacity ramp: Potential to scale manufacturing footprint by an additional 800 crore units per annum; first objective is 400 crore, then 800 crore, with management confident capacity will be sold out as it comes online.
- US registration: Plan to get the plant registered for the US market to utilize infrastructure for both Europe and the US.
- Revenue contribution: Will generate some revenues in the first year itself from Teva supply arrangements and own products; once capacity expansion objectives are achieved, the plant could contribute perhaps ₹200 crores per quarter.
Mark Saldanha: "With new capacity of that magnitude, and that volume, will definitely give tremendous potential for growth, and that's where we are, you have to invest today to see returns tomorrow..."
Margin Dynamics & Cost Environment
- Gross margin pressure: Q2 gross margin declined 80 bps YoY to 50.7% due to pricing pressure, while H1 EBITDA margin declined 210 bps YoY to 17.3% mainly on higher cost of materials and freight in the last quarter.
- Freight costs easing: Freight costs have come down from historically high levels, which is helping the bottom line after previously eroding it.
- Input cost trajectory: Input costs have cooled from an upward trend to a downward trend, but at a very slow pace; global market scenarios remain volatile due to the Russia-Ukraine war and China lockdowns.
- OTC contract risk: OTC contracts are longer-duration, so when input costs and freight rose, margins were squeezed because the company was locked into pricing; the easing cost environment should now support better OTC profitability.
- API backward integration: Moving to backward integrate into API manufacturing for core molecules on captive consumption, with potential cost synergies and gross/EBITDA margin expansion of 500 bps; first DMF filing planned for mid-2023, with profitability upside expected only towards end of FY23-24.
- Margin outlook: If the trend of input cost and freight cost reduction continues, the 20% EBITDA margin number could be seen next year, though management remains cautious on forward-looking statements given global volatility.
Mark Saldanha: "No one has a crystal ball to see as to what impact it will have. Obviously, China has got its own challenges of lockdown. So again, we are very cautious in terms of giving any forward-looking statement, but as of today, it is looking positive, it is improving to that level."
US Market: Pricing, Penetration & Pipeline
- Generic Rx pricing erosion: Witnessed high single-digit price erosion in the generic Rx business in the US, driven by consolidation in the distribution channel that has intensified competition.
- OTC vs Rx dynamics: OTC pricing pressure was not as severe as Rx because the OTC distribution channel remains fragmented and diversified, though OTC contracts lock in pricing when costs rise.
- Market penetration: Management characterizes current US penetration as minimal, with tremendous growth potential in market share on the existing product portfolio; new products described as "icing on the top."
- ANDA pipeline: Expecting about 5 ANDA approvals in 2023, then 7–8 per year on average, with approximately 30 products being worked on.
- Near-term growth drivers: Awarded items planned for commercialization by March 2023, with a healthier roadmap for the next financial year.
Mark Saldanha: "Well, obviously, it's just at the tip of the iceberg, we have not penetrated anything significantly, but we are still doing decent numbers."
UK & Other International Markets
- UK performance: Business is doing well in H1 because of a much bigger and more diversified product portfolio (Relonchem 100+ MAs, Bells ~60 MAs), consistent deliveries, and becoming a preferred sourcing partner, leading to better market share.
- UK outlook: Expected to get stronger because of the product pipeline and the nature of products getting approved, with better visibility and growth potential from product pipelines coming into that market in the next 12 months.
- Australia: Faced pricing pressure and profitability challenges for the first time due to freight and supply chain disruptions, though growth continues; market remains small in absolute numbers due to small population.
- Emerging markets: Doing fairly well, expanding into different geographies with a strengthening product portfolio; revenue expected to double in the next couple of years.
Mark Saldanha: "I think outlook is only going to get stronger, because of the product pipeline that we have and the nature of the products that are getting approved."
Product Mix, R&D & Strategic Initiatives
- OTC/Rx mix shift: OTC now represents 65% of the business versus Rx at 35%, a shift from the historical 50-50 split; expected to remain around 65-35 going forward, give or take a percentage point.
- Rx-to-OTC switch: Management sees the Rx-to-OTC switch opportunity as "very lucrative," with potential growth demand in both segments.
- R&D spend: Aim to increase R&D spends to 4–5% of sales in coming years, up from 2.1% in H1 FY23.
- Product launches: Plan to launch several high-value products in the next two years.
- E-commerce platform: Launched less than a year ago; growing but still very small.
- Regulatory status: UK plants have been audited by UK regulators; US facility maintains GMP status with no observations and is audited once or twice a year.
Mark Saldanha: "The only difference between OTC and Rx, is Rx, the distribution channel has consolidated tremendously, and that consolidation has affected competition and price erosion, which has taken place as a cascading impact of that, while OTC is still fragmented and diversified, where that is concerned."
M&A & Europe Expansion
- Pan-Europe focus: Actively exploring M&A across the pan-Europe market for front-end market authorizations, similar to the UK presence; looking for a platform to launch products with distribution channels where value can be added.
- Deal status: In active dialogue over the last six months; some dialogues are closer than others but nothing concrete, described as at very initial stages; no other geographies on the plate currently.
- Timeline uncertainty: Management declined to specify a timeline, stating a deal could happen within a couple of months or maybe in a year's time, and declined to specify a potential target size because no target is in hand.
- Access Healthcare: Small acquisition completed in June 2022, contributed approximately ₹12 crores in Q2 FY23, with goodwill of ~₹17 crores recorded.
Mark Saldanha: "It's difficult to say because we don't have a target right now in hand, so it's difficult to actually put a potential target."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Teva acquisition close | Transaction finalized, subject to closing conditions | April 1, 2023 |
| Teva capacity ramp | Scale to 400 crore units (first objective), then 800 crore units | Over the next two years |
| Teva total investment | ₹200 crores (acquisition + Capex), funded via internal accruals | Spread over next two years |
| First API DMF filing | File a couple of DMFs for captive consumption molecules | Mid-2023 |
| API profitability upside | Cost advantage and margin improvement from backward integration | End of 2023 or early 2024 |
| US ANDA approvals | ~5 approvals expected | Calendar year 2023 |
| US awarded items commercialization | Awarded items planned for launch | By March 2023 |
| Revenue milestone | Cross ₹2,000 crores | Next financial year (FY24) |
| Revenue milestone | Reach ₹3,000 crores within 1/3rd the time taken to go from ₹1,000 to ₹2,000 crores | After crossing ₹2,000 crores |
| Emerging markets revenue | Double revenue | Next couple of years |
| R&D spend target | Increase to 4–5% of sales | Coming years |
| EBITDA margin | 20% number visible if input cost and freight reduction trend continues | Next year |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Operating revenue | ₹452.6 cr, +25.5% YoY |
| US & North America revenue | ₹190.3 cr, +13.7% YoY |
| EU & UK formulation revenue | ₹193.5 cr, +32.6% YoY |
| Australia & New Zealand revenue | ₹43.9 cr, +39% YoY |
| Rest of world revenue | ₹24.9 cr, +56.4% YoY |
| Gross margin | 50.7%, declined 80 bps YoY from 51.4% |
| EBITDA | ₹80.3 cr, +33.6% YoY |
| EBITDA margin | 17.7%, improved 110 bps YoY from 16.6% |
| Profit after tax | ₹60.1 cr, +29.9% YoY |
| EPS | ₹1.52, +36.3% YoY |
| R&D expense (H1 FY23) | ₹18.7 cr, 2.1% of sales |
| Cash and bank balance | ₹335 cr as of 30 September 2022 |
| Global OTC/Rx mix | 65% OTC, 35% Rx; historically 50-50 |
| ANDA approvals expected in 2023 | ~5, then 7–8 per year average |
| FY23 revenue trending | ₹1,800 cr |